Erez Chimovits bought $14.0M of Upstream Bio (UPB)

Executed Oct 15 2024, disclosed Oct 17 2024, 2 days later.

Value, as filed

$14.0M

825,000 sh across 2 lots

Executed

Oct 15 2024

the trade date, as filed

Disclosed

Oct 17 2024

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+11.8%

+14.4% from execution

Over the 21 trading sessions from the disclosed entry session (Oct 17 2024), the stock returned +11.8% (delay-adjusted); from the execution session (Oct 15 2024), +14.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

Erez Chimovits Director profile →

Erez Chimovits (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Braveheart Bio, Inc. (BRVE). Across 1 priced purchase filing, the average 21-session return was -10.0% from execution and +5.0% from disclosure (delay-adjusted; derived). The largest single filing was $34.9M of BRVE (1,940,000 sh across 2 lots, as filed), executed Aug 7.

The name

UPB UPB UPB · 3 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→